Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Benzodiazepines (BZD) and benzodiazepine receptor agonists (zolpidem, zaleplon, zopiclone, altogether Z-drugs) are most commonly prescribed for the treatment of insomnia. However, long-term use of BZD/Z-drugs is associated with major adverse events including, but not limited to, falls and fractures, domestic and traffic accidents, confusion, cognitive impairment, Alzheimer's disease and cancer. The prolonged use of these drugs is thought to be related to severe withdrawal symptoms and potential dependency. The chronic and extensive use of BZD/Z drugs has become a public health issue and has led to multiple campaigns to reduce both prescription and consumption of BZD/Z-drugs. Prolonged-release (PR) melatonin is the first of a new class of melatonin receptor agonist drugs that has demonstrated clinically relevant efficacy on improving quality of sleep and morning alertness, with a good safety profile. OBJECTIVE: This study aimed to analyze and evaluate the impact of anti-BZD/Z-drugs campaigns and the availability of alternative pharmacotherapy (PR-melatonin) on the consumption of BZD and Z-drugs in several European countries. METHODS: Annual sales data from nine European countries were extracted from the IMS sales database and analyzed to determine whether trends in use of these treatment options were attributed to campaigns and/or availability and affordability of safer alternatives on the market. RESULTS: Campaigns aiming to reduce the use of BZD/Z-drugs failed when they were not associated with the availability and market uptake of PR-melatonin. The reimbursement of PR-melatonin supports better penetration rates and a higher reduction in sales for BZD/Z-drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality Associated With Sleep Duration and Insomnia
Kripke, D. F., Garfinkel, L., Wingard, D. L., Klauber, M. R., & Marler, M. R. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.2.131 · Cited by 1,614
Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005) · BMJ · doi:10.1136/bmj.38623.768588.47 · Cited by 1,161 · cited 2×
“In patients over 60 years of age, chronic BZD or Z-drug use carries the risk of exacerbations of pre-existing psychomotor or cognitive impairment, which may result in an increased risk of falls, motor vehicle collisions, household accidents or confusion and memory problems [27].”
Background(2009) · Sleep · doi:10.5665/sleep/32.1.55 · Cited by 664 · cited 1×
“Direct and indirect costs of insomnia represent a substantial societal economic burden [4].”
BackgroundBenzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511 · cited 1×
“Unlike Z-drugs, BZD could be used for other indications such as epilepsy or anxiety [56, 57].”
BackgroundOhayon, M. M. (1997) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00002-2 · Cited by 423
Hajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00491.x · Cited by 404
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
Benzodiazepines and Injurious Falls in Community Dwelling Elders
Pariente, A., Dartigues, J.-F., Benichou, J., Letenneur, L., Moore, N., & Fourrier-Réglat, A. (2008) · Drugs & Aging · doi:10.2165/00002512-200825010-00007 · Cited by 172 · cited 1×
“A meta-analysis of the risks and benefits of these therapeutic options in elderly patients reported statistically significant improvements in sleep, but also reported a statistically significant risk of adverse events [12, 13], including life-threatening ones [14].”
BackgroundKunz, D., Bineau, S., Maman, K., Milea, D., & Toumi, M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.638284 · Cited by 37
Self-citation
Cited by
Morin, C. M., Drake, C. L., Harvey, A. G., Krystal, A. D., Manber, R., Riemann, D., & Spiegelhalder, K. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.26 · Cited by 746
Barger, L. K., Flynn-Evans, E. E., Kubey, A., Walsh, L., Ronda, J. M., Wang, W., Wright, K. P., & Czeisler, C. A. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70122-x · Cited by 277
Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers
La, A. L., Walsh, C. M., Neylan, T. C., Vossel, K. A., Yaffe, K., Krystal, A. D., Miller, B. L., & Karageorgiou, E. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181145 · Cited by 83
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Why are benzodiazepines not yet controlled substances?
Moore, N., Pariente, A., & Bégaud, B. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2190 · Cited by 62
Self-citation
Metadata
- Authors
- Clay, E., Falissard, B., Moore, N., & Toumi, M.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2012-11-01
- Volume
- 69
- Issue
- 4
- Pages
- 1-10
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2056917744
- Cited by
- 65
- References
- 10
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.